2. Immunology/Inflammation
  3. Interleukin Related
  4. Tucotuzumab celmoleukin

Tucotuzumab celmoleukin  (Synonyms: EMD 273066; huKS-IL2)

Cat. No.: HY-P991214 Purity: 98.797%
COA
SDS
Technical Support

Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine. Tucotuzumab celmoleukin consists of the following components: an IgG1 monoclonal antibody targeting human EpCAM antigen, and two molecules of IL2. Tucotuzumab celmoleukin binds to EpCAM. Tucotuzumab celmoleukin exerts anti-tumor effects on colon adenocarcinoma in synergy with radiofrequency ablation. Tucotuzumab celmoleukin can be used in research related to colon adenocarcinoma and colon cancer.

For research use only. We do not sell to patients.

CAS No. : 339986-90-2

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

Tucotuzumab celmoleukin Related Antibodies

Top Publications Citing Use of Products

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine. Tucotuzumab celmoleukin consists of the following components: an IgG1 monoclonal antibody targeting human EpCAM antigen, and two molecules of IL2. Tucotuzumab celmoleukin binds to EpCAM. Tucotuzumab celmoleukin exerts anti-tumor effects on colon adenocarcinoma in synergy with radiofrequency ablation. Tucotuzumab celmoleukin can be used in research related to colon adenocarcinoma and colon cancer[1][2].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target[1]

IL-2

 

In Vivo

Single treatment with tucotuzumab celmoleukin (15-37.5 μg; intratracheal administration; once daily for 5 consecutive days or 2 doses) moderately inhibits the growth of CT26-KS colon adenocarcinoma in BALB/c mice; when combined with partial radiofrequency ablation (RFA), it induces synergistic tumor growth inhibition[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c (6- to 8-wk-old female; injected s.c. with 5×105 CT26-KS colon adenocarcinoma cells in the abdomen)[1]
Dosage: 15 μg (subtherapeutic single agent; combination therapy); 37.5 μg (combination therapy)
Administration: i.t.; daily for 5 days (15 μg); 2 doses (37.5 μg)
Result: Resulted in moderate tumor growth suppression compared with no treatment (P = 0.002), but no complete tumor resolution when used alone with subtherapeutic dosing (15 μg i.t.
days 11-15).
Achieved synergistic tumor growth suppression (P < 0.001 on day 16 and P < 0.002 on day 19 versus all other groups), complete tumor resolution in 8 of 16 mice, and significantly enhanced survival compared with untreated mice (P < 0.001), RFA alone (P < 0.001), or Tucotuzumab celmoleukin alone (P = 0.002) when combined with partial RFA.
Across all experiments, combination therapy resulted in complete tumor resolution in 14 of 28 mice (P < 0.001 versus no treatment, P = 0.024 versus RFA alone, P = 0.003 versus Tucotuzumab celmoleukin alone).
Showed tumor growth suppression not significantly different from the 5-day 15 μg dose regimen, and both were superior to RFA alone (P < 0.005 on day 25) when given as two 37.5 μg i.t.
doses (days 10 and 14) in combination with RFA.
Resulted in complete resolution of the treated abdominal tumor in 7 of 15 mice and complete resolution of the untreated distant flank tumor in 8 of 15 mice as a single agent (15 μg i.t.
days 10-14).
Enabled tumor-free mice treated alone or in combination with RFA to reject rechallenges with CT26-KS tumor cells, and 3 of 3 mice treated alone to reject parental CT26 tumor rechallenges.
Induced 3% of CD4+ T cells and 5-6% of CD8+ T cells expressing IFN-γ after in vitro stimulation with CT26-KS cells in splenocytes from mice treated alone, with similar low proportions expressing GM-CSF.
Clinical Trial
Gene ID

4072  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Tucotuzumab celmoleukin]
Shipping

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • IgG1-kappa-[PROTEIN]2
Biological Activity
  • Immobilized EpCAM/TROP1 Protein, Human (HEK293, His, HY-P70154) can bind Tucotuzumab celmoleukin. The EC50 for this effect is 21.36 ng/mL.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tucotuzumab celmoleukin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tucotuzumab celmoleukin339986-90-2EMD 273066 huKS-IL2EMD273066EMD-273066Interleukin RelatedILT-cellcolon adenocarcinomacolon cancerCT26-KS colon adenocarcinomaEpCAMFc receptorBALB/c miceCD4 T cellCD8 T cellIL-2 receptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tucotuzumab celmoleukin
Cat. No.:
HY-P991214
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.